Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
Launched by RECORDATI GROUP · Aug 10, 2023
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called ISBUS, is focused on developing a new tool to measure the symptoms and challenges faced by people living with Idiopathic Multicentric Castleman Disease (iMCD). The goal is to create a scale that can help understand how this condition affects daily life, allowing for better support and treatment options for patients.
To be eligible for this trial, participants must be adults aged 18 and older who have been diagnosed with iMCD and can speak and understand English. Unfortunately, children under 18, individuals without a diagnosis of iMCD, or those who cannot communicate in English will not be able to participate. Since the trial is not yet recruiting, there will be more information available in the future about what participants can expect, including any assessments or questionnaires they might complete to share their experiences with symptoms. This research aims to improve care for those living with this rare disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of idiopathic Multicentric Castleman Disease (iMCD)
- • Adults (aged 18+ years)
- • Fluent in English
- Exclusion Criteria:
- • No diagnosis of iMCD
- • Children (aged \< 18 years)
- • Not able to understand or communicate in English
- • People lacking the capacity to consent
About Recordati Group
Recordati Group is a global pharmaceutical company headquartered in Milan, Italy, specializing in the development and commercialization of innovative medicines and healthcare solutions. With a strong focus on rare diseases, specialty pharmaceuticals, and generic products, Recordati is committed to improving patient outcomes through research-driven initiatives and a robust pipeline of therapeutic options. The company emphasizes collaboration and integrity in its clinical trials, ensuring adherence to the highest ethical and scientific standards while striving to address unmet medical needs worldwide. Leveraging its extensive expertise and global presence, Recordati aims to deliver impactful solutions that enhance the quality of life for patients across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anju Keetharuth, PhD
Principal Investigator
University of Sheffield
Philip Powell, PhD
Principal Investigator
University of Sheffield
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported